Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck

被引:23
作者
Choe, Mi Sun [1 ]
Chen, Zhuo [1 ]
Klass, Carmen M. [1 ]
Zhang, Xin [1 ]
Shin, Dong M. [1 ]
机构
[1] Emory Univ, Winship Canc Inst, Dept Hematol Oncol, Atlanta, GA 30322 USA
关键词
D O I
10.1158/1078-0432.CCR-06-2959
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The addition of molecular targeted agents to enhance the cytotoxicity of chemotherapeutic agents is a promising strategy in cancer treatment. The combination of cyclooxygenase-2 inhibitors and epidermal growth factor receptor tyrosine kinase inhibitors, such as celecoxib and ZD1839 (gefitinib), was reported to achieve synergistic cell growth inhibition in squamous cell carcinoma of the head and neck. Therefore, we postulated that the addition of celecoxib and ZD1839 to docetaxel, a cytotoxic agent, might further increase antitumor activity. Experimental Design:The combination of celecoxib, ZD1839, and docetaxel was studied for its effect on cell growth and apoptosis by cell growth inhibition and Annexin V assays. The relevant molecular targets of these agents and apoptotic markers were examined by immunoblotting analyses in the presence or absence of these three drugs. Morphologic changes of the microtubule cytoskeleton, a known target of docetaxel, were also evaluated by staining for alpha-tubulin after the combination treatment. Results: We showed that this triple combination significantly enhanced cell growth inhibition and docetaxel-induced apoptosis. Docetaxel mainly induced caspase-8 activation, whereas the addition of celecoxib and ZD1839 augmented the caspase-8 activation and enhanced caspase-9 activation. One of the underlying mechanisms for augmentation of docetaxel-induced apoptosis by celecoxib and ZD1839 is to further inhibit the activation of prosurvival pathway molecules, such as extracellular signal-regulated kinase and AKT and the promotion of aberrant apoptosis. Conclusions: Our studies suggest that the combination of docetaxel with a cyclooxygenase-2 inhibitor and an epidermal growth factor receptor tyrosine kinase inhibitor may further improve efficacy of docetaxel and other taxane-based therapies in squamous cell carcinoma of the head and neck.
引用
收藏
页码:3015 / 3023
页数:9
相关论文
共 47 条
[21]  
Huisman C, 2002, CLIN CANCER RES, V8, P596
[22]   Celecoxib activates a novel mitochondrial apoptosis signaling pathway [J].
Jendrossek, V ;
Handrick, R ;
Belka, C .
FASEB JOURNAL, 2003, 17 (09) :1547-+
[23]  
Jordan MA, 1996, CANCER RES, V56, P816
[24]   Microtubules as a target for anticancer drugs [J].
Jordan, MA ;
Wilson, L .
NATURE REVIEWS CANCER, 2004, 4 (04) :253-265
[25]   Prognostic value of activated Akt expression in oral squamous cell carcinoma [J].
Lim, J ;
Kim, JH ;
Paeng, JY ;
Kim, MJ ;
Hong, SD ;
Lee, JI ;
Hong, SP .
JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (11) :1199-1205
[26]  
MacKeigan JP, 2002, CLIN CANCER RES, V8, P2091
[27]   MEK inhibition enhances paclitaxel-induced tumor apoptosis [J].
MacKeigan, JP ;
Collins, TS ;
Ting, JPY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) :38953-38956
[28]   Akt activation correlates with adverse outcome in tongue cancer [J].
Massarelli, E ;
Liu, DD ;
Lee, JJ ;
El-Naggar, AK ;
Lo Muzio, L ;
Staibano, S ;
De Placido, S ;
Myers, JN ;
Papadimitrakopoulou, VA .
CANCER, 2005, 104 (11) :2430-2436
[29]   Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines [J].
McDaid, HM ;
Horwitz, SB .
MOLECULAR PHARMACOLOGY, 2001, 60 (02) :290-301
[30]  
Moraitis D, 2005, CANCER RES, V65, P664